Haemorrhagic stroke is more common in adults with chronic kidney disease (CKD) than in the general population. A recent study reports that low concentrations of LDL significantly increase the risk of haemorrhagic stroke. This finding challenges the concept of aggressive lipid lowering in patients with high cardiovascular risk, including those with CKD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Power, A. Stroke in dialysis and chronic kidney disease. Blood Purif. 36, 179–183 (2013).
Sun, L. et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat. Med. 25, 569–574 (2019).
Wang, X. et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 44, 1833–1839 (2013).
Palmer, S. C. et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. 5, Cd007784 (2014).
Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
Giugliano, R. P. et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137, 1571–1582 (2018).
Holdaas, H. Rosuvastatin in diabetic hemodialysis patients. J. Am. Soc. Nephrol. 22, 1335–1341 (2011).
Zhou, Z. et al. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke 50, 396–404 (2019).
Orsi, F. A. et al. Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review. Semin. Thromb. Hemost. https://doi.org/10.1055/s-0039-1687911 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Van Laecke, S. Lipid lowering and risk of haemorrhagic stroke in CKD. Nat Rev Nephrol 15, 667–669 (2019). https://doi.org/10.1038/s41581-019-0201-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-019-0201-0
